Table 3 Assessment of body composition at baseline and at the end of the intervention perioda

From: Double-blind, placebo-controlled pilot trial of L-Leucine-enriched amino-acid mixtures on body composition and physical performance in men and women aged 65–75 years

Body composition variables Group A (n=8) Group B (n=8) Group C (n=9)
  Baseline Week 12 % ES Baseline Week 12 % ES Baseline Week 12 %
Total LTM (kg) 44.8±7.1 44.8±7.2 0.2±2.4 −0.4 45.5±8.9 46.0±9.1b 1.1±1.1 0.2 42.6±8.9 43.0±9.3 0.8±1.3
Total FM (kg) 27.8±11.4 28.5±11.2 4.3±6.7 0.4 25.6±6.2 25.7±6.0 0.5±2.6 −0.2 24.9±9.9 25.1±9.7 1.5±6.3
Percentage BF (%) 36.0±10.5 36.7±9.7 3.3±6.1 0.5 34.8±6.6 34.7±6.5 −0.4±2.1 −0.2 35.2±11.2 35.2±11.0 0.4±4.7
Total BMC (kg) 2.6±0.5 2.6±0.5 0.1±1.4 −0.3 2.5±0.6 2.5±0.6 0.0±1.0 −0.4 2.4±0.5 2.4±0.5 0.4±1.0
Total BMD (g/cm2) 1.1±0.1 1.1±0.1 0.2±1.2 0.5 1.1±0.2 1.1±0.2 0.3±1.6 0.5 1.1±0.1 1.1±0.1 −0.4±1.1
  1. Abbreviations: A, standard essential amino-acid mixture (containing 20% leucine); B, modified amino-acid mixture (containing 40% leucine); C, placebo; BMC, bone mineral content; BMD, bone mineral density; BF, body fat; ES, Effect Size; FM, fat mass; LTM, bone mineral-free lean tissue mass; %, mean percentage change from baseline to week 12.
  2. aAll values are means±standard deviations.
  3. bDenotes significantly different from baseline value (P<0.05). ME=mean of the experimental group, MP=mean of the placebo group. ES Cohen’s d=(ME-MP)/SD pooled).